"Shotgun approach" to functional claiming fatal to RNA editing claims in Australia

The Australian Patent Office (APO) has issued a decision finding that ProQR Therapeutics II B.V.'s RNA editing antisense oligonucleotide claims are invalid for lack of sufficiency and support due to broad functional limitations and "unbridled" medical use claims in Wrays Solutions Pty Ltd v ProQR Therapeutics II B.V. [2026] APO 36. 

The decision demonstrates that the APO's approach to broad functional claiming is largely aligned with that in Europe and other major jurisdictions, while the approach to medical use claims reflects an arguably stricter standard that may require additional limitations to be sufficiently enabled.

Brief background 

The claims at issue relate to chemically modified antisense oligonucleotides (AONs) that recruit a cell’s naturally occurring ADAR enzyme to achieve conversion of a target adenosine to inosine (A-to-I editing) in RNA by modifications in a "Central Triplet" of three sequential nucleotides. The claimed modifications are functionally defined in claim 1, namely, "wherein 1, 2 or 3 nucleotides in said Central Triplet comprise a sugar modification and/or a base modification to render the AON more stable and/or more effective in inducing deamination of the target adenosine". 

Various other dependent and independent claims further define the modifications in structural terms, and medical uses in the treatment of various genetic disorders are also claimed. 

"Shot gun approach" to functional claiming 

The claims were opposed by a strawperson for being overly broad with respect to the functional claim features. By contrast, the Applicant argued it was entitled to the full breadth of the claims because the claimed AONs were directed to a "breakthrough invention" involving modifying the Central Triplet to solve the long-standing problem of deploying RNA editing in therapy. The Applicant submitted that the skilled person would be readily able to select suitable modifications to achieve the invention. 

The Delegate acknowledged that broad claims can be enabled where the specification teaches a relevant principle of general application. However, while the Examples in this case demonstrate that chemical modifications of the Central Triplet can improve stability and effectiveness, some of these modifications also resulted in neutral or detrimental effects. An expert for the Opponent described the Examples as a "shot gun approach" to determining whether modifications both inside and outside the Central Triplet resulted in any benefit. Further, the evidence did not support the Applicant's contention that modification of the Central Triplet was unconventional in the art at the priority date. 

Accordingly, the Delegate did not consider that the specification provides any teaching beyond the exemplified embodiments that would enable a skilled person to reliably produce more stable and/or effective AONs relative to their unmodified counterparts without undertaking an extensive research project. 

"Unbridled" medical use claims 

Overly broad Kat
The medical use claims were also challenged on the basis that they encompass an "unbridled" range of genetic diseases without limitation to A-to-I edit-dependent genetic diseases, and because the specification does not teach how to identify an appropriate site for clinically relevant A-to-I modification. The Delegate considered that, to do so, the skilled person "must first conduct their own research program to see if there is a suitable RNA to target for an A-to-I edit for treating any given genetic disease". This was not conducive to a finding of sufficiency or support. 

Non-naturally occurring AONs 

The Opponent also opposed the claims as lacking clarity due to the presence of a proviso that "the AON is not a naturally occurring AON" because it is not possible for a skilled person to determine whether a given AON is naturally occurring. On this basis, the Opponent also argued that the proviso rendered the claims unpatentable subject matter because it acknowledged that the claims otherwise encompass naturally occurring AONs, which are not patentable in Australia. 

The Delegate rejected this argument as being a "cautionary approach of a scientist unwilling to exclude the theoretical possibility that such an oligonucleotide might occur in nature, rather than any genuine uncertainty as to the scope of the claim". Rather, the proviso represented "no more than a belts and braces approach to highlight its deliberately engineered character". In any case, the claimed AONs require modifications to the Central Triplet that increase stability and/or effectiveness, and are therefore not naturally occurring. 

Final thoughts 

As is the case at many Patent Offices around the world, the APO applies a strict standard for the assessment of sufficiency and support, such that functional features can be difficult to retain unless there is a relevant principle of general application disclosed in the specification (which can present its own problems: IPKat). 

This also extends to medical use claims in Australia, where even first medical uses of a new product typically must be limited by a biological pathway or mechanism of action to sufficiently support the breadth of the claims. This approach differs from that often seen in Europe, where EPC 2000 style purpose-limited product claims are commonly allowed without such limitations, even in relation to second medical uses.

 Interestingly, the counterpart European patent was also opposed but a variation of the functional claims survived on all grounds, including lack of sufficiency (although that decision is currently under appeal). This is significant because the Australian courts have often emphasised that Australia's Raising the Bar amendments to the Patents Act in 2013 were intended to align the sufficiency and support requirements with those of the UK and Europe. 

In the present Australian case, the Applicant has been given the opportunity to amend the claims to overcome the Delegate's findings. It also remains possible for this decision to be appealed to the Federal Court.

Do you want to reuse the IPKat content? Please refer to our Policies section. If you have any queries or requests for permission, please get in touch with the IPKat team.
Print | Share by email

Comments

← Previous Post Next Post →